Drug Profile
BNC 105
Alternative Names: BNC 105P; BNC-105Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Iliad Chemicals
- Developer Bionomics
- Class Anisoles; Antineoplastics; Benzofurans; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Malignant-mesothelioma; Renal cell carcinoma
- Phase I/II Ovarian cancer
- Discontinued Chronic lymphocytic leukaemia; Colorectal cancer
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Australia (unspecified route)
- 23 Feb 2023 Discontinued - Preclinical for Colorectal cancer in Australia (IV)
- 17 Feb 2021 EmpathBio collaborates with Bionomics to explore a combination drug treatment for Post-traumatic stress disorder